IL1B and B-cell non-Hodgkin lymphoma: Given the B-cell-derived origin of plasma cells as well as the pathways shared in the pathogenesis of lymphoid and plasma cell malignancies, targeting IL-1β signaling presents a potential therapeutic approach for B-cell lymphomas.